Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(3)

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NVrOcm57S2WubDDWbYFjcWyrdImgRZN{[Xl? NGC5epYzNjVvMUWgcm0> NGm0cmU4OiCq NXjZVWJQcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NHrJb2gzPTd7MEmwOy=>
U2932  NVvwfodmS2WubDDWbYFjcWyrdImgRZN{[Xl? NHnqdWMzNjVvMUWgcm0> M4nsc|czKGh? NX3mPWNvcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NYjvcm5GOjV5OUC5NFc>
OCI-LY7 NEHHfm5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml3UNk42NTF3IH7N MkXmO|IhcA>? NVX5XHBZcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MWKyOVc6ODlyNx?=
Farage NFXucmJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUeyMlUuOTVibl2= NXvMRmRSPzJiaB?= Mn7ibY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MVmyOVc6ODlyNx?=
LY7/EBV M1PFPWNmdGxiVnnhZoltcXS7IFHzd4F6 NX7XPIVlOi53LUG1JI5O NH62OoE4OiCq M{nFZ4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NWnUXXdVOjV5OUC5NFc>
U2932/EBV NIfQT5lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoGzNk42NTF3IH7N MoTTO|IhcA>? Mor6bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NUKwUYx[OjV5OUC5NFc>
HCT116 NWDxe3NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;BOU02ODByIH7N NVS3SIJOOjRiaB?= NEjIWXJFVVOR NV3IVWV3cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MYiyOVQ6OjVzNR?=
ACH-2 NGfCZ5NHfW6ldHnvckBCe3OjeR?= NF3aU48yNTlibl2= NVXTNJRUOjRiaB?= NH2wR4JqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v Ml\XNlUyPDl2Nke=
MCF-10A M{nYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnxUIVKSzVyPUCuNVfDuTBwMEGgcm0> NHjkS5UzPDl3NEi1Oi=>
MCF-7 M4i4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\STWM2OD1zLkGwxtExNjJyIH7N NYPIUpR[OjR7NUS4OVY>
SK-BR-3 NIrUWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;uTWM2OD1zLkCwxtExNjN3IH7N MWGyOFk2PDh3Nh?=
MDA-MB-231 NUXMOZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LRWGlEPTB;MD62POKyOC5zNDDuUS=> NV;zRZB7OjR7NUS4OVY>
PC3 M{f6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GzemlEPTB;MT62OeKyOC5|NTDuUS=> NXTZR3pTOjR7NUS4OVY>
HCT116 NI\JZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L3SGlEPTB;MT6wNOKyOC5yMDDuUS=> NUjl[FJxOjR7NUS4OVY>
HCT116-p21-/- MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon5TWM2OD1zLkK2xtExNjN5IH7N NGDKRYkzPDl3NEi1Oi=>
S1 NUn0eVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTdwNkhCtVAvOjlibl2= NXX6e|h2OjR7NUS4OVY>
SW620 M3zUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjKdFNKSzVyPUCuPVPDuTBwMkmgcm0> NVLFZ2hKOjR7NUS4OVY>
LOX-IMVI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwOEhCtVAvODNibl2= MViyOFk2PDh3Nh?=
UACC-62 NXyxVYh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HkZmlEPTB;MD61OuKyOC5zNjDuUS=> MVGyOFk2PDh3Nh?=
MDA-MB-435 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H6bmlEPTB;MD65NOKyOC5yNjDuUS=> M4LWPVI1QTV2OEW2
SF-295 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPQVHM3UUN3ME2wMlg5yrFyLkG1JI5O NWKxUXhxOjR7NUS4OVY>
A549 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jFXWlEPTB;MT6yOuKyOC5{NDDuUS=> NEn6c5ozPDl3NEi1Oi=>
H460 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvTWM2OD1{LkW4xtExNjhyIH7N MW[yOFk2PDh3Nh?=
EKVX MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDIOWZKSzVyPUGuN|PDuTBwM{Sgcm0> MmO0NlQ6PTR6NU[=
H146 M1Wzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMkNCtVAvODdibl2= M{jWNVI1QTV2OEW2
H526 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2cmVKSzVyPUCuNVXDuTBwMEOgcm0> NHq4OoMzPDl3NEi1Oi=>
HuT-78 NXz2fVBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLOc5RKSzVyPUGuO|PDuTBwNESgcm0> NXe5Xo9POjR7NUS4OVY>
HA M{LKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTFd3B5OC54MkWtNVBvVQ>? NXHHeoJlPDhiaB?= NHzxenlqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? MWSyOFc4OTVzMB?=
MS-275 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f5S|AvPjJ3LUGwcm0> NY\w[WlMPDhiaB?= NFvifGZqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? M1jrRlI1PzdzNUGw
CD4 T NHXjXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DnblQ5KGh? MoH6SWM2OD12LkZCtVEvOCCwTR?= NGn4UJozPDd{MkS1OC=>
CD4 T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjqPWY1QCCq MUnDR|UxRTFyN9MxNVI3KG6P NFTSflkzPDd{MkS1OC=>
CD4+ T MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3PZYVNTUN3ME2zJI5O MnnUNlQ1QTVzMEW=
A549 M1HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNQKBmzFyMNMgcm0> M37HN|I1NzN4L{S4JIg> NWrZUZdncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NFv0NGQzPDR6NUe5PS=>
JJN3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDG[FMzPC92ODDo M2L0emVEPTB:MfMAjY5OQyB2OPMAjYg> M3vkblI1ODNyMUWw
OPM-2 NF;L[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3BTYVPOjRxNEigbC=> M2\wV2VEPTC|PUJihKlvVTtiNElihKlp NILmb5AzPDB|MEG1NC=>
RPMI-8226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzaSY1qOjRxNEigbC=> NF7RO|ZGSzVyc{2xMljjiImwTUugOFjjiImq NHXCZ5kzPDB|MEG1NC=>
U266 NH7YNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\VW|I1NzR6IHi= MWXFR|Uxez1zMPMAjY5OQyB2OPMAjYg> NWPN[YhCOjRyM{CxOVA>
CA46 M13pdWFxd3C2b4Ppd{BCe3OjeR?= NULSe5p[PiCq MnTkbY5lfWOnczDicJVvfCCjcH;weI9{cXN? M{jDS|I{QTZ4MU[0
DG75 NHH4SIJCeG:ydH;zbZMhSXO|YYm= NUfhZZVGPiCq M4\RfYlv\HWlZYOgco8h[XCxcITvd4l{ MnK1NlM6PjZzNkS=
Ramos MVjBdI9xfG:|aYOgRZN{[Xl? NFXSTmc3KGh? M2m0[4lv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> M1HUclI{QTZ4MU[0
ST486 MmD4RZBweHSxc3nzJGF{e2G7 MXe2JIg> MV\pcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= MmfDNlM6PjZzNkS=
HuT78 MmPxRZBweHSxc3nzJGF{e2G7 NVPsemF5OS9zMD:xNFAhdk1? NHzjWJk1QCCq MXjpcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P MWmyN|U{Ojd|Mh?=
DpVp35 NHL3PXNCeG:ydH;zbZMhSXO|YYm= Mmj6NU8yOC9zMECgcm0> MW[0PEBp MkW0bY5lfWOnczDicJVvfCCjcH;weI9{cXN? MVWyN|U{Ojd|Mh?=
DpVp50 NGr4NXJCeG:ydH;zbZMhSXO|YYm= M2nPdlEwOTBxMUCwJI5O M4D1TlQ5KGh? NIDPO2dqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MVyyN|U{Ojd|Mh?=
DpP75  MUPBdI9xfG:|aYOgRZN{[Xl? MWixM|ExNzFyMDDuUS=> NHTFSFU1QCCq NG\HdndqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M4HNOVI{PTN{N{Oy
SKOV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PqUFHjiJN{MH7N NFvZflg4OiCq MnrnSG1UVw>? NGDpN21z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M2O2TlI{ODFyM{S4
Brca1 WT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7IUVUy6oDVMkDuUS=> M2W1R|czKGh? NX3YXmxKTE2VTx?= MlTWdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NIDsXHQzOzBzMEO0PC=>
Brca1 Null MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOx5qCUOjCwTR?= MnfSO|IhcA>? MkK4SG1UVw>? NUjES5NuemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? M4nUPFI{ODFyM{S4
OVCAR-8  Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2fHF3OeLCk{Kwcm0> NFjCV5k4OiCq NHK2T3FFVVOR NIC4XHNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MV2yN|AyODN2OB?=
NCI/ADR-RES NUfFdHhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGx5qCUOjCwTR?= Ml3IO|IhcA>? NFHsVGJFVVOR MYPy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MY[yN|AyODN2OB?=
HCT116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:1JI5ONTVyIN88US=> M2P3WVI1KGh? Mm[xSG1UVw>? NF;Fc3BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NVLYNlI2OjJ7MkS5OVg>
RKO M2jYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLhOUBvVS13MDFOwG0> NE\pO5kzPCCq MXrEUXNQ M1q0[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M3zNWFIzQTJ2OUW4
CO115 NUnKSJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu0OUBvVS13MDFOwG0> NYPLeWRKOjRiaB?= NGjKOGJFVVOR M4fzSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NGX0UpAzOjl{NEm1PC=>
HFS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn2OUBvVQ>? MlnNNlQwPDhxN{KgbC=> M{[1[olvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NILLZYMzOjFyNkK4Ni=>
LNCaP MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3WN3Y2KG6P MnniNlQwPDhxN{KgbC=> M1fpZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MnfHNlIyODZ{OEK=
A549 M{f3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyyU|I2KG6P M4DKZ|I1NzR6L{eyJIg> MVfpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 NXvtUXlqOjJzME[yPFI>
697  NFraV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHGTWM2OOLCiU5ihKkzNjYEoH7N NXr0U4ZjOjF3M{iyNVY>
697-R NF\ORVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfU[JpKSzVy4pEJQgKBkThwNtMgcm3DqA>? MWiyNVU{QDJzNh?=
HUT78 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO5Wm5kUUN3ME2xJI5O M3LtelIyOTl6NUS1
THJ-16T NUPI[GxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u3T|Ehdk1? MW[yOEBp MkTVbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4\rR|IxQDFyNU[4
HCT116 Mn;MSpVv[3Srb36gRZN{[Xl? NYfpUWloOjBibl2= M4iyflghcA>? NInmcGxud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= NVW1SVhIOjB5M{m0OVQ>
B104  MWXGeY5kfGmxbjDBd5NigQ>? Mn21NkBvVQ>? M{noS|I1NzR6L{eyJIg> MoXMbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi NFHxVZMzODZ6NkWwOS=>
HL-60  MmXjR5l1d3SxeHnjbZR6KEG|c3H5 NE\OWlQyNTVyMDDuUS=> MV[yOEBp MVTpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MUSyNFYzPDF4Mx?=
HP100 MXzDfZRwfG:6aXPpeJkhSXO|YYm= MWmxMVUxOCCwTR?= NILyfm0zPCCq MX3pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MYCyNFYzPDF4Mx?=
HL-60  NETlWZpHfW6ldHnvckBCe3OjeR?= NVPWc2pCOTBibl2= NWfmcIhTPC94L{G2JIg> MnjqbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq MoTxNlA3OjRzNkO=
HP100 M{HmPGZ2dmO2aX;uJGF{e2G7 NYr6OHhVOTBibl2= M2jGN|QwPi9zNjDo NHHxXpRqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= NGnJZ|czODZ{NEG2Ny=>
HL-60  M3XKOmZ2dmO2aX;uJGF{e2G7 MXyxNE02ODBibl2= MkD0OEBp NV\qWW1E\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg Mn3aNlA3OjRzNkO=
HP100 MWrGeY5kfGmxbjDBd5NigQ>? MYixNE02ODBibl2= NGfY[5I1KGh? MYHk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MYqyNFYzPDF4Mx?=
11z NX;4eW9TU2mwYYPlJGF{e2G7 NXnydpRuOy1zMECgcm0> NFX1O4Nz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= MoDqNlA3ODVzNES=
SKOV-3 MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LCTFQwQC9zNjDuUS=> MV:0PEBp MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MVyyNFQxPDV4NB?=
OVCAR-3 M2i5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi0M|gwOTZibl2= M3fsNVQ5KGh? Mm\qbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MWmyNFQxPDV4NB?=
HBL-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWeyMVExKG6P Mne1NlQhcA>? NIO1eJRKSzVyPUSuN{BvVQ>? NWLhNJlROjByNkiwPFA>
Jeko-1 NXHycZJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDidGszNTVyIH7N M4LPe|I1KGh? NEnwRZpKSzVyPUGxJI5O MW[yNFA3QDB6MB?=
Granta-519 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljSOU01OCCwTR?= NEW3b48zPCCq MVfJR|UxRTV6LkWgcm0> NFjH[o0zODB4OEC4NC=>
L1236 M{Sz[WN6fG:2b4jpZ4l1gSCDc4PhfS=> MlK0NUBvVS1zMECg{txO MUW0PEBp MorNSWM2OD1yLkC3JO69VQ>? MmTONVkzOzN2N{C=
L428 MXPDfZRwfG:6aXPpeJkhSXO|YYm= NYfwN2FsOSCwTT2xNFAh|ryP NEHRfWY1QCCq MYjFR|UxRTBwNEOg{txO MmHRNVkzOzN2N{C=
KM-H2 MmO5R5l1d3SxeHnjbZR6KEG|c3H5 M{HS[|Ehdk1vMUCwJO69VQ>? M37vUlQ5KGh? MnrvSWM2OD1yLkW4JO69VQ>? MWSxPVI{OzR5MB?=
L540Cy NELFeIZEgXSxdH;4bYNqfHliQYPzZZk> M4LWelEhdk1vMUCwJO69VQ>? M3v2dVQ5KGh? M3u4[mVEPTB;MD6xOkDPxE1? NYfaO5k5OTl{M{O0O|A>
G401 NVLTNmx2TnWwY4Tpc44hSXO|YYm= NIjkZ2cyOCCwTR?= NXXrcIdsOjRxNEivO|IhcA>? MYHEUXNQ MnL0bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MUixPVIzOTV6Nh?=
STM91-01 NIq3N5dHfW6ldHnvckBCe3OjeR?= M4LlOlExKG6P NH7OSYgzPC92OD:3NkBp NXK4[ZZYTE2VTx?= M361UIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NYPqXHZ5OTl{MkG1PFY>
SJSC  MYXGeY5kfGmxbjDBd5NigQ>? MYWxNEBvVQ>? M1TmXlI1NzR6L{eyJIg> NEi4NHJFVVOR Ml[zbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NHXzfZMyQTJ{MUW4Oi=>
BT16  NXG4d2pqTnWwY4Tpc44hSXO|YYm= NEi4OW8yOCCwTR?= NUXpUpJROjRxNEivO|IhcA>? M3vxO2ROW09? NF35Wo9qdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NGHFOHAyQTJ{MUW4Oi=>
NCI-H1299 NFHjV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXlPG52UUN3ME20MlbDuTBwMjDu[{9udA>? MmnENVkyPzl6OUC=
NCI-2882 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jKTWlEPTB;MT62xtExNjB2IH7nM41t M3jFUlE6OTd7OEmw
HCC95 NUPRPGtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWwPYZKSzVyPUKuOeKyOC5yNTDu[{9udA>? MnfLNVkyPzl6OUC=
NCI-H23 M2Tne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HPUmlEPTB;Mj65xtExNjJibnevcYw> MXSxPVE4QTh7MB?=
NCI-H157 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HDUmlEPTB;MT62xtExNjB{IH7nM41t MVGxPVE4QTh7MB?=
NCI-H460 M{K1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvhe3pWUUN3ME2yMlHDuTBwMEegcocwdWx? Mmr3NVkyPzl6OUC=
NCI-H1975 NYDRbWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQ[3BnUUN3ME2xMlPDuTBwMESgcocwdWx? NW[3RnlvOTlzN{m4PVA>
NCI-H820 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:5Uo83UUN3ME2yMlTDuTBwMTDu[{9udA>? Mo\TNVkyPzl6OUC=
NCI-H1650 NILBXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHROJg2UUN3ME20MlnDuTBwMzDu[{9udA>? M1T3WlE6OTd7OEmw
DTC1 M2jiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHMcYNJUUN3ME2wMlUyKG6P MXuxPFU3PjJ2Nh?=
KAO Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnR[VRKSzVyPUCuPVEhdk1? MoLjNVg2PjZ{NE[=
SU-CCS-1 NFzw[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLnN2VEUUN3ME2wMlg6KG6P M3vKelE5PTZ4MkS2
SYO-1 NWflb4FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNkegcm0> MXmxPFU3PjJ2Nh?=
FUJI M2XTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnLcIZKSzVyPUGuN|Ehdk1? NWjnXJpiOTh3Nk[yOFY>
SKNMC M2rxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYraSFZnUUN3ME2xMlE4KG6P NXfjWXZJOTh3Nk[yOFY>
402-91 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwMk[gcm0> Ml3JNVg2PjZ{NE[=
1765-92 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwN{egcm0> NIn1VokyQDV4NkK0Oi=>
JN-DSRCT-1 NYq1N4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHsTWM2OD1zLkK1JI5O M{\kSVE5PTZ4MkS2
NMS-2PC NF3ZfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwOEGgcm0> MUexPFU3PjJ2Nh?=
HL60 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3TRYZpUUN3ME2xMlg3KG6P Mk\QNVg2PjZ{NE[=
A549 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrETWM2OD1|LkK0JI5O NFO2PXYyQDV4NkK0Oi=>
SW480 M4jMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTPTXY3UUN3ME2yMlY6KG6P NVjHPFZZOTh3Nk[yOFY>
MCF7 NVj6[2RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jJW2lEPTB;Mz61OUBvVQ>? M2q4fFE5PTZ4MkS2
PC-3 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD1{LkWxJI5O NXi3[GR5OTh3Nk[yOFY>
MMRU MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4XnF{UUN3ME2yMlU4KG6P NIji[XgyQDV4NkK0Oi=>
Hs68 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPMTWM2OD1-MUCgcm0> M{TwNlE5PTZ4MkS2
hMSC-001F Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRT5zMDDuUS=> NGG4cocyQDV4NkK0Oi=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID